Table 1.

Baseline Values and Changes in NMR Determined Lipid Parameters after 12 weeks Rosiglitazone Therapy Compared to Placebo (n=28)

	Placebo (n=12)		Rosiglitazone (n=16)		p-value
	Baseline	Change	Baseline	Change
VLDL Particles (nmol/L)
Total	123.2 ± 14.1	−2.6 ± 14.5	127.9 ± 15.7	23.5 ± 10.8	0.15
Large	30.7 ± 7.4	−0.9 ± 3.3	15.1 ± 4.0	5.3 ± 2.4	0.13
Medium	58.3 ± 10.0	−1.6 ± 12.9	70.1 ± 9.2	4.0 ± 8.4	0.71
Small	34.2 ± 5.9	−0.1 ± 6.5	42.7 ± 6.5	14.3 ± 6.9	0.15
IDL Particles (nmol/L)	60.7 ± 10.9	−18.6 ± 9.2	42.6 ± 11.4	8.3 ± 8.6	0.04
LDL Particles (nmol/L)
Total	1670.8 ± 205.6	−200.4 ± 76.9	1422.3 ± 129.3	242.3 ± 112.5	0.006
Large	157.9 ± 42.9	57.3 ± 39.1	242.2 ± 66.1	103.7 ± 103.9	0.71
Small (total)	1452.3 ± 181.4	−239.0 ± 102.7	1137.6 ± 148.3	130.4 ± 127.8	0.04
Medium Small	293.2 ± 32.3	−34.6 ± 21.8	238.7 ± 29.9	8.50 ± 25.7	0.23
Very Small	1159.2 ± 150.2	−204.3 ± 86.6	899 ± 119.1	121.6 ± 103.7	0.03
HDL Particles (μmol/L)
Total	25.7 ± 1.32	1.0 ± 1.1	29.8 ± 1.8	−2.1 ± 1.5	0.12
Large	1.87 ± 0.61	0.54 ± 0.4	3.05 ± 0.80	−1.13 ± 0.6	0.03
Medium	7.3 ± 1.5	1.4 ± 1.4	4.5 ± 1.1	3.3 ± 1.3	0.31
Small*	16.5 ± 1.3	−0.9 ± 1.3	22.3 ± 1.5	−4.3 ± 1.9	0.17
Mean Particle Size (nm)
VLDL	63.3 ± 4.2	2.3 ± 1.9	58.7 ± 3.3	0.2 ± 2.2	0.50
LDL	19.8 ± 0.1	0.28 ± 0.16	20.2 ± 0.2	−0.03 ± 0.18	0.23
HDL	8.51 ± 0.10	0.21 ± 0.07	8.63 ± 0.09	−0.65 ± 0.49	0.003

Values expressed are mean ± SEM.

^*Significant difference between treatment groups at baseline (p<0.01).